Aadi Bioscience

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aadi Bioscience reports robust FYARRO sales and optimistic outlook for 2023

Aadi Bioscience showcased strong sales performance and financial stability in 2022.
The company's strengths lie in successful product launches, collaborations, and trial outcomes.
Challenges include managing expenses and meeting expectations for future data releases.
Excitement for 2023 signals potential growth opportunities and continued success.

Aadi Bioscience reports revenue growth and clinical progress in Q1

Aadi Bioscience demonstrated strong performance with revenue growth, progress in clinical trials, and a solid financial position.
The company's strengths lie in its product pipeline, clinical trial advancements, and financial stability, positioning it well for future growth.
While facing challenges in sales growth, trial timelines, and global expansion, Aadi Bioscience has opportunities to diversify its portfolio and explore new markets.

Aadi Bioscience reports robust Q2 earnings and expands pipeline offerings

Aadi Bioscience's Q2 performance reflects strong revenue growth, promising pipeline developments, and a solid financial position, positioning the company for future success.
While facing challenges in managing expenses and clinical trials, the company has opportunities to leverage its momentum, expand its market reach, and drive innovation.
Investors should take note of Aadi Bioscience's strategic advancements and financial stability, signaling potential for growth and value creation in the biopharmaceutical sector.

Aadi Bioscience reports solid Q3 results, advances cancer treatment innovations

Aadi Bioscience's Q3 performance reflects financial stability, increased expenses, and progress in advancing nab-Sirolimus for mutated cancers.
The company's strengths lie in new leadership, innovative treatment potential, and a tumor-agnostic trial approach, positioning it for future success.
Challenges include addressing analyst inquiries, meeting trial timeline goals, and managing financial resources effectively amidst growth and innovation.
Opportunities abound in potentially transforming cancer treatment, showcasing advancements, and expanding the pipeline with innovative approaches.

Aadi Bioscience reports robust sales growth and advances in cancer trials

Aadi Bioscience's strong financial performance in 2023, driven by robust FYARRO sales and a focus on operational efficiency, sets a solid foundation for future growth and innovation.
While challenges exist in managing R&D expenses and trial timelines, the company's strategic measures and positive outlook position them well to capitalize on opportunities in expanding their therapeutic reach.
With ongoing trials showing promising results and a proactive approach to presenting new data, Aadi Bioscience remains committed to advancing novel treatments and delivering value to patients and investors alike.

Aadi Bioscience reports steady Q1 sales and optimistic trial progress

Aadi Bioscience's Q1 performance reflects steady sales and strong cash position supporting future operations.
The company's focus on advancing clinical trials and strategic program alignment positions it for future growth.
Challenges in sales and collaboration changes present areas for ongoing monitoring and strategic adjustments.

Aadi Bioscience reports robust Q2 sales and advances in nab-Sirolimus trials

Aadi Bioscience's Q2 performance reflects steady growth in FYARRO sales and progress in nab-Sirolimus trials for various tumor types.
Despite challenges in meeting expectations and market dynamics, the company's strong financial position and confidence in its products are notable strengths.
With a cash runway into Q4 2025 and a promising pipeline, Aadi is poised for growth and success in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.

Shares have lost half their value since reverse merger with Aerpio Pharmaceuticals. Aadi aims to deliver on the broad potential of mTOR inhibition via nab technology to achieve wide therapeutic index and greater target suppression.

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

LOS ANGELES , Sept. 1, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the Company will be participating in and hosting one-on-one meetings at the following conferences during September: Citi's 17th Annual BioPharma Conference, September 7-8, 2022, in Boston, MA Morgan Stanley's 20th Annual Global Healthcare Conference, September 12-14, 2022, in New York, NY   Neil Desai, Ph.D.

Aadi Bioscience Announces Participation in Upcoming September Investor Conferences

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Marcy Graham - SVP of IR and Corporate Communications Neil Desai - President and CEO Brendan Delaney - COO Loretta Itri - Chief Medical Officer Scott Giacobello - CFO Conference Call Participants Boris Peaker - Cowen Jiale Song - Jefferies Robert Burns - H.C. Wainwright Operator Good day and thank you for standing by.

Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q2 2022 Results - Earnings Call Transcript

FYARRO® (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022 PRECISION 1 Phase 2 tumor-agnostic registration-directed trial continues enrollment and rapid site activation at major cancer centers and large community networks; preliminary data expected 1H23 Conference call to be held today at 8:30 am EDT LOS ANGELES , Aug. 10, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2022. "We continue to progress in key areas after our first full quarter following FYARRO's launch.

Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update

Company to Host Conference Call and Webcast on August 10 LOS ANGELES , July 28, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, August 10, 2022 at 8:30 am EDT (5:30 am PDT) to report second quarter 2022 financial results and provide recent corporate updates. Conference Call Information   Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com.

Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update

LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of additions posted by FTSE Russell on June 3, 2022.

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fireside chat at 10am ET on Thursday, June 9, 2022.

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference

LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications.

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting

LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi's executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Miami, FL.

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Andrew Quan - VP, Business Development & Corporate Strategy Neil Desai - Founder, President, CEO, Secretary & Director Brendan Delaney - COO Loretta Itri - Chief Medical Officer Scott Giacobello - CFO & Treasurer Conference Call Participants Boris Peaker - Cowen and Company Ahu Demir - Ladenburg Thalmann & Co. Joseph Catanzaro - Piper Sandler & Co. Jiale Song - Jefferies Operator Greetings, and welcome to the Aadi Bioscience, Inc. First Quarter 2021 Earnings Conference Call. [Operator Instructions].

Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q1 2022 Results - Earnings Call Transcript

LOS ANGELES, May 12, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced financial results for the first quarter of 2022 and provided a corporate update.

UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update

LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced partnerships with prominent next generation sequencing (NGS) providers and leaders in genomic testing and profiling, including Foundation Medicine, Tempus and others. We expect these collaborations to expedite patient identification for the ongoing PRECISION 1 trial of nab-sirolimus in patients harboring tumors with inactivating alterations in TSC1 or TSC2 genes.

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

J-Code, Effective July 1st, Will Enable a Streamlined Reimbursement Process for FYARRO™ J-Code, Effective July 1st, Will Enable a Streamlined Reimbursement Process for FYARRO™

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

Company to hold conference call on May 12th at 8:30 am EDT Company to hold conference call on May 12th at 8:30 am EDT

Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022

LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi's executive team will participate at the Jefferies “Biotech on the Bay” Summit, to be held in-person in Miami, FL April 26-27, 2022.

Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit

- First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000 advanced cancer patients in 2030

Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)

FDA grants Fast Track designation for nab-sirolimus for the treatment of adult and adolescent patients with Tuberous Sclerosis Complex 1 and 2 (“TSC1” and “TSC2”) alterations FDA grants Fast Track designation for nab-sirolimus for the treatment of adult and adolescent patients with Tuberous Sclerosis Complex 1 and 2 (“TSC1” and “TSC2”) alterations

Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

-FYARRO™ approved November 22, 2021 and launched February 23, 2022-

Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

LOS ANGELES, March 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq:AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will participate in a panel discussion on Tumor-Agnostic Development and one-on-one investor meetings at Cowen's 42nd Annual Health Care Conference, to be held virtually March 7-9, 2022.

Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowen's 42nd Annual Health Care Conference

– FYARRO™ added to NCCN® Guidelines as the only preferred mTOR inhibitor to treat malignant PEComa – – PRECISION-1 tumor agnostic study for TSC1 or TSC2 alterations is open for enrollment –

Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa

LOS ANGELES, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. The presentation will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET.

Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference

Aadi Bioscience receives FDA approval of Fyarro for treatment of patients with PEComa. Fyarro (ABI-009) can be expanded upon in two specific gene pathways known as TSC1 and TSC2; this could bring access to thousands of new patients.

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

The stock price of Aadi Bioscience Inc (NASDAQ: AADI) increased by over 25% pre-market today. This is why it happened.

News for Aadi Bioscience Stock (AADI)